Publication:
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

dc.contributor.coauthorColombo, N.
dc.contributor.coauthorSessa, C.
dc.contributor.coauthordu Bois, A.
dc.contributor.coauthorLedermann, J.
dc.contributor.coauthorMcCluggage, W. G.
dc.contributor.coauthorMcNeish, I.
dc.contributor.coauthorMorice, P.
dc.contributor.coauthorPignata, S.
dc.contributor.coauthorRay-Coquard, I.
dc.contributor.coauthorVergote, I.
dc.contributor.coauthorBaert, T.
dc.contributor.coauthorBelaroussi, I.
dc.contributor.coauthorDashora, A.
dc.contributor.coauthorOlbrecht, S.
dc.contributor.coauthorPlanchamp, F.
dc.contributor.coauthorQuerleu, D.
dc.contributor.coauthorBaert, T.
dc.contributor.coauthorBanerjee, S.
dc.contributor.coauthorBelaroussi, I.
dc.contributor.coauthorBlecharz, P.
dc.contributor.coauthorBruchim, I.
dc.contributor.coauthorCibula, D.
dc.contributor.coauthorColombo, N.
dc.contributor.coauthorConcin, N.
dc.contributor.coauthorDavidson, B.
dc.contributor.coauthorDashora, A.
dc.contributor.coauthorDevouassoux-Shisheboran, M.
dc.contributor.coauthordu Bois, A.
dc.contributor.coauthorFerrero, A.
dc.contributor.coauthorGlasspool, R.
dc.contributor.coauthorGonzalez-Martin, A.
dc.contributor.coauthorHeinzelmann-Schwarz, V.
dc.contributor.coauthorJoly, F.
dc.contributor.coauthorKim, J. W.
dc.contributor.coauthorKridelka, F.
dc.contributor.coauthorLedermann, J.
dc.contributor.coauthorLorusso, D.
dc.contributor.coauthorMahner, S.
dc.contributor.coauthorMcCluggage, W. G.
dc.contributor.coauthorMcNeish, I.
dc.contributor.coauthorMikami, M.
dc.contributor.coauthorMirza, M. R.
dc.contributor.coauthorMorice, P.
dc.contributor.coauthorNicum, S.
dc.contributor.coauthorOlbrecht, S.
dc.contributor.coauthorO'Donnell, D. M.
dc.contributor.coauthorPautier, P.
dc.contributor.coauthorPlanchamp, F.
dc.contributor.coauthorPignata, S.
dc.contributor.coauthorQuerleu, D.
dc.contributor.coauthorRay-Coquard, I.
dc.contributor.coauthorRodolakis, A.
dc.contributor.coauthorSehouli, J.
dc.contributor.coauthorSelcukbiricik, F.
dc.contributor.coauthorSessa, C.
dc.contributor.coauthorSingh, N.
dc.contributor.coauthorTan, D. S. P.
dc.contributor.coauthorTimmerman, D.
dc.contributor.coauthorTognon, G.
dc.contributor.coauthorvan der Velden, J.
dc.contributor.coauthorVergote, I.
dc.contributor.coauthorWitteveen, P. O.
dc.contributor.coauthorZeimet, A. G.
dc.contributor.kuauthorSelçukbiricik, Fatih
dc.contributor.kuprofileFaculty Member
dc.contributor.unitKoç University Hospital
dc.date.accessioned2024-11-09T11:55:09Z
dc.date.issued2019
dc.description.abstractThe development of guidelines recommendations is one of the core activities of the European Society for Medical Oncology (ESMO) and European Society of Gynaecologial Oncology (ESGO), as part of the mission of both societies to improve the quality of care for patients with cancer across Europe. ESMO and ESGO jointly developed clinically relevant and evidence-based recommendations in several selected areas in order to improve the quality of care for women with ovarian cancer. The ESMO-ESGO consensus conference on ovarian cancer was held on 12-14 April 2018 in Milan, Italy, and comprised a multidisciplinary panel of 40 leading experts in the management of ovarian cancer. Before the conference, the expert panel worked on five clinically relevant questions regarding ovarian cancer relating to each of the following four areas: pathology and molecular biology, early-stage and borderline tumours, advanced stage disease and recurrent disease. Relevant scientific literature, as identified using a systematic search, was reviewed in advance. During the consensus conference, the panel developed recommendations for each specific question and a consensus was reached. The recommendations presented here are thus based on the best available evidence and expert agreement. This article presents the recommendations of this ESMO-ESGO consensus conference, together with a summary of evidence supporting each recommendation.
dc.description.fulltextYES
dc.description.indexedbyWoS
dc.description.indexedbyScopus
dc.description.issue5
dc.description.openaccessYES
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.sponsorshipESMO and ESGO funds
dc.description.versionPublisher version
dc.description.volume30
dc.formatpdf
dc.identifier.doi10.1093/annonc/mdz062
dc.identifier.embargoNO
dc.identifier.filenameinventorynoIR01780
dc.identifier.issn0923-7534
dc.identifier.linkhttps://doi.org/10.1093/annonc/mdz062
dc.identifier.quartileQ1
dc.identifier.urihttps://hdl.handle.net/20.500.14288/817
dc.identifier.wos482490300006
dc.keywordsOvarian cancer
dc.keywordsAdjuvant treatment
dc.keywordsSurgery
dc.keywordsPathology
dc.keywordsMolecular biology
dc.keywordsRecurrent disease
dc.languageEnglish
dc.publisherOxford University Press (OUP)
dc.relation.grantnoNA
dc.relation.urihttp://cdm21054.contentdm.oclc.org/cdm/ref/collection/IR/id/8403
dc.sourceAnnals of Oncology
dc.subjectOncology
dc.titleESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.kuauthorSelçukbiricik, Fatih

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
8403.pdf
Size:
729.27 KB
Format:
Adobe Portable Document Format